Arrowhead Pharmaceuticals shares are down about 3% in today’s session, with trading chatter centered on recently filed insider activity rather than a new pipeline headline. The company’s investor site shows multiple late-April SEC filings, including a Form 4 filed April 24, 2026 with a transaction date of April 23, 2026, signaling additional insider selling that can weigh on sentiment in a stock that has rallied sharply into 2026.

Arrowhead’s SEC filings list a Form 4 dated April 24, 2026 (document date April 23, 2026) reporting changes in beneficial ownership for an insider (James C. Hamilton). Separately, a Form 4 document posted on Arrowhead’s IR site describes an open-market sale of 15,000 shares at an average price around $66.23 under a 10b5-1 plan, adding to the near-term supply overhang that traders often treat as a caution flag even when the sale is pre-planned.

On days without a fresh clinical update or earnings release, biotech names can move on positioning, risk appetite, and incremental sentiment shifts. A new insider-sale print can amplify profit-taking—especially after strong prior performance—because it can be interpreted as insiders locking in gains, even when sales are executed under 10b5-1 arrangements.

The next near-term scheduled event on the company calendar is Arrowhead’s webcast and conference call for fiscal 2026 second-quarter results on May 7, 2026. Until then, ARWR trading may remain sensitive to additional ownership/filing updates, option flow, and broader biotech tape action.